ALKERMES PLCG01767105IE00B56GVS1505/20/2026To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER826270FOR82627FOR ARGENX SE04016X101US04016X101905/06/2026The 2025 remuneration report (advisory non-binding voting item)SECTION 14A SAY-ON-PAY VOTESISSUER4423020FOR442302FOR ARROWHEAD PHARMACEUTICALS, INC.04280A100US04280A100703/19/2026Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER73713010FOR7371301FOR AVIDITY BIOSCIENCES, INC.05370A108US05370A108802/26/2026To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.SECTION 14A SAY-ON-PAY VOTESISSUER85157490FOR8515749FOR CELCUITY INC.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER11893710FOR1189371FOR CYTOKINETICS, INCORPORATED23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER17462540FOR1746254FOR DAMORA THERAPEUTICS, INC.36322Q206US36322Q206606/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER37830000FOR3783000FOR DAMORA THERAPEUTICS, INC.36322Q206US36322Q206606/17/2026To conduct an advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER378300001 YEAR3783000FOR DEFINIUM THERAPEUTICS, INC.24477V105CA24477V105806/11/2026To consider, and if deemed advisable, approve the amendment to the Definium Thrapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Equity Incentive Plan") to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan by 5,000,000 common shares.SECTION 14A SAY-ON-PAY VOTESCOMPENSATIONISSUER49203730FOR4920373FOR KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER25422980FOR2542298FOR KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER33980930FOR3398093FOR MADRIGAL PHARMACEUTICALS INC.558868105US558868105706/17/2026Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER4000770FOR400077FOR MANNKIND CORPORATION56400P706US56400P706905/20/2026To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind's proxy statement for the Annual Meeting;SECTION 14A SAY-ON-PAY VOTESISSUER2047520FOR204752FOR MERUS N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTESISSUER13582090FOR1358209FOR OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER46811150FOR4681115FOR OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER468111501 YEAR4681115FOR REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER8594650FOR859465FOR STRUCTURE THERAPEUTICS, INC.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER51407240FOR5140724FOR TAYSHA GENE THERAPIES, INC.877619106US877619106106/01/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER203903830FOR20390383FOR TAYSHA GENE THERAPIES, INC.877619106US877619106106/01/2026To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2039038301 YEAR20390383FOR UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER13733340FOR1373334FOR UNIQURE N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER137333401 YEAR1373334FOR UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER19500830FOR1950083FOR VERA THERAPEUTICS, INC.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER49930610FOR4993061FOR VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3110570FOR311057FOR VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER31105701 YEAR311057FOR WHITEHAWK THERAPEUTICS, INC.00032Q104US00032Q104006/11/2026To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the ''Executive Compensation'' section of the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER34717520FOR3471752FOR XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER57777770FOR5777777FOR XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER577777701 YEAR5777777FOR ZEALAND PHARMA A/SK9898X127DK006025781403/26/2026APPROVE REMUNERATION REPORT (ADVISORY VOTE)SECTION 14A SAY-ON-PAY VOTESISSUER18165580FOR1816558FOR